Physician profile
Steven E Weisman
NPI 1720038656
$5,133.18
in general payments reported to CMS, 2019-2025
25 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $824 · 2021: $753 · 2022: $696 · 2023: $602 · 2024: $679 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,345.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,739.69 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $515.35 | 2019-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $493.71 | 2019-2022 | |
| Lilly USA, LLC | $442.55 | 2020-2025 | Mounjaro, Jardiance |
| Novo Nordisk INC | $403.70 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Esperion Therapeutics, INC. | $289.05 | 2020-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.64 | 2019-2023 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $159.03 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $157.69 | 2025 | Voquezna |
| Allergan, INC. | $143.11 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $130.57 | 2022-2025 | |
| Abbvie INC. | $77.33 | 2020-2023 | Viberzi, Linzess |
| Medtronic, INC. | $59.64 | 2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Eisai INC. | $55.17 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $46.93 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $34.95 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.61 | 2025 | Jardiance |
| Mylan Specialty L.P. | $23.91 | 2020 | |
| Edwards Lifesciences Corporation | $23.61 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.13 | 2022 | |
| Nevro Corp. | $16.74 | 2020 | |
| Pfizer INC. | $14.59 | 2024 | |
| Merck Sharp & Dohme LLC | $14.27 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.58 | 2022 | |
| Avanir Pharmaceuticals, INC. | $12.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Weisman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.